Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | Precision medicine in lymphoid malignancies

Wyndham Wilson • 4 Dec 2015
ASH 2015
B-Cell Lymphoma Ibrutinib

Wyndham Wilson, MD, PhD from the National Cancer Institute, Bethesda, MD talks about the concept of precision medicine in lymphoid malignancies. He discusses a study presented at the American Society of Hematology (ASH) 2015 Annual Meeting, looking at key mutations in the B-cell receptor (BCR) signaling cascade within diffuse large B-cell lymphoma (DLBCL). The study revealed that certain mutations were associated with a better response to certain drugs, such as ibrutinib. These findings are important as we strive to improve precision in medicine and ensure patients are receiving the best treatment for their disease type.

More from Wyndham Wilson

4:17
Ibrutinib in DLBCL: revelations from further analysis of PHOENIX
Wyndham Wilson • 2 Jul 2019
1:12
Liquid biopsy to measure MRD
Wyndham Wilson • 2 Jul 2019
2:30
ViPOR regimen for R/R B-cell lymphoma
Wyndham Wilson • 2 Jul 2019
2:49
Liquid biopsy making strides forward in NHL: detection of ctDNA and mutations
Wyndham Wilson • 2 Jul 2019

Related Videos

1:13
Antibody-drug conjugates for the treatment of lymphoma
Pau Abrisqueta • 5 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
4:09
Real-world safety and efficacy of liso-cel in R/R large B-cell lymphoma
Jennifer Crombie • 9 Dec 2023
2:06
Odronextamab in CAR-T relapsed diffuse large B-cell lymphoma
Jennifer Crombie • 9 Dec 2023
The content of VJHemOnc is intended for healthcare professionals